Advertisement

Socioeconomic Disparities and Risk Factors in Patients Presenting With Ischemic Priapism: A Multi-Institutional Study

      ABSTRACT

      Objectives

      To evaluate contemporary clinical presentations of priapism, their association with socioeconomic characteristics, and the role of prescribing providers in priapism episodes in a large cohort of patients managed at 3 major academic health systems.

      Methods

      We identified all consecutive patients presenting with ischemic priapism to the emergency departments of three major academic health systems (2014 –2019). Demographic characteristics, priapism etiologies, and clinical management were evaluated. Univariable and multivariable analyses were used to assess the contribution of socioeconomic characteristics and the role of prescribing providers in priapism episodes.

      Results

      We identified 102 individuals with a total of 181 priapism encounters. Hispanic race, lower income quartile, sickle-cell disease, and illicit drug use were associated with increased risk of recurrent episodes. Of ICI users, 57% received their prescriptions from non-urological medical professionals (NUMPs); the proportion with recurrent episodes was higher for NUMPs compared to urologists (24% vs 0%, P = 0.06) with no demographic differences identified between patients treated by either group.

      Conclusion

      Socioeconomic disparities exist among patients presenting with recurrent episodes of priapism, potentially highlighting systemic issues with access to care and patient education. With most patients who developed ischemic priapism from ICI being prescribed these medications by NUMPs, further investigation is required to elucidate the prescribing and counseling patterns of these providers. Increased awareness of disparities and complications may improve patient safety.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Montague DK
        • Jarow J
        • Broderick GA
        • et al.
        American urological association guideline on the management of priapism.
        J Urol. 2003; 170: 1318-1324https://doi.org/10.1097/01.ju.0000087608.07371.ca
        • Roghmann F
        • Becker A
        • Sammon JD
        • et al.
        Incidence of priapism in emergency departments in the United States.
        J Urol. 2013; 190: 1275-1280https://doi.org/10.1016/j.juro.2013.03.118
        • Stein DM
        • Flum AS
        • Cashy J
        • Zhao LC
        • McVary KT
        Nationwide emergency department visits for priapism in the United States.
        J Sex Med. 2013; 10: 2418-2422
        • Shigehara K
        • Namiki M
        Clinical management of priapism: a review.
        World J Mens Health. 2016; 34: 1-8https://doi.org/10.5534/wjmh.2016.34.1
        • Zentgraf M
        • Ludwig G
        • Ziegler M
        How safe is the treatment of impotence with intracavernous autoinjection?.
        Eur Urol. 1989; 16: 165-171
        • Reddy AG
        • Alzweri LM
        • Gabrielson AT
        • Leinwand G
        • Hellstrom WJG
        Role of penile prosthesis in priapism: a review.
        World J Mens Health. 2018; 36: 4-14https://doi.org/10.5534/wjmh.17040
        • Spycher MA
        • Hauri D
        The ultrastructure of the erectile tissue in priapism.
        J Urol. 1986; 135: 142-147https://doi.org/10.1016/s0022-5347(17)45549-2
        • Anele UA
        • Burnett AL
        Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors.
        J Sex Med. 2015; 12: 713-719https://doi.org/10.1111/jsm.12816
        • Houman JJ
        • Eleswarapu SV
        • Mills JN
        Current and future trends in men's health clinics.
        Transl Androl Urol. 2020; 9: 116-122https://doi.org/10.21037/tau.2019.08.33
        • Hsiang WR
        • Honig S
        • Leapman MS
        Evaluation of online telehealth platforms for treatment of erectile dysfunction.
        J Urol. 2020; 205: 330-332https://doi.org/10.1097/JU.0000000000001378
        • Fantus R
        • Darves-Bornoz A
        • Hehemann M
        • et al.
        Examining online traffic patterns to popular telemedicine websites for evaluation and treatment of erectile dysfunction.
        J Urol. 2020; 203: e613
        • Rodler S
        • von Büren J
        • Buchner A
        • et al.
        Epidemiology and treatment barriers of patients with erectile dysfunction using an online prescription platform: a cross-sectional study.
        Sex Med. 2020; 8: 370-377https://doi.org/10.1016/j.esxm.2020.04.001
        • Burnett AL
        • Edwards NC
        • Barrett TM
        • Nitschelm KD
        • Bhattacharyya SK
        Addressing health-care system inequities in the management of erectile dysfunction: a call to action.
        Am J Men's Health. 2020; 141557988320965078https://doi.org/10.1177/1557988320965078
        • Klein JB
        • Nguyen CT
        • Saffore L
        • Modlin III C
        • Modlin CS
        Racial disparities in urologic health care.
        J Nat Med Assoc. 2010; 102: 108-118
        • Aytaç IA
        • Araujo AB
        • Johannes CB
        • Kleinman KP
        • McKinlay JB
        Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal massachussetts male aging study.
        Soc Sci Med. 2000; 51: 771-778
        • Rezaee ME
        • Gross MS
        Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors?.
        J Sex Med. 2020; 17: 1579-1582
        • Giuliano F
        • Jackson G
        • Montorsi F
        • Martin-Morales A
        • Raillard P
        Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.
        Int J Clin Pract. 2010; 64: 240-255
        • Shahinyan RH
        • Amighi A
        • Carey AN
        • et al.
        Direct-to-consumer internet prescription platforms overlook crucial pathology found during traditional office evaluation of young men with erectile dysfunction.
        Urology. 2020; 143: 165-172https://doi.org/10.1016/j.urology.2020.03.067
        • Saigal CS
        • Wessells H
        • Pace J
        • et al.
        Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population.
        Arch Intern Med. 2006; 166: 207-212
        • Pohl J
        • Pott B
        • Kleinhans G
        Priapism: a 3-phase concept of management according to aetiology and prognosis.
        BJU. 1986; 58: 113-118
        • Saffon Cuartas JP
        • Sandoval-Salinas C
        • Martínez JM
        • Corredor HA
        Treatment of priapism secondary to drugs for erectile dysfunction.
        Adv Urol. 2019; 6214921https://doi.org/10.1155/2019/6214921
        • Burnett AL
        • Nehra A
        • Breau RH
        • et al.
        Erectile dysfunction: AUA guideline.
        J Urol. 2018; 200: 633-641https://doi.org/10.1016/j.juro.2018.05.004